Sequoia Financial Advisors LLC Invests $645,000 in Corcept Therapeutics Incorporated $CORT

19 Sep 2026, 08:18 by Danessa Lincoln · The Markets Daily

Sequoia Financial Advisors LLC purchased a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 7,423 shares of the biotechnology company’s stock, valued at approximately $645,000.

Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Corcept Therapeutics in the 2nd quarter valued at about $1,080,964,000. First Trust Advisors LP lifted its position in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after acquiring an additional 1,480,059 shares during the period. Geode Capital Management LLC lifted its position in Corcept Therapeutics by 38.0% during the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after acquiring an additional 734,646 shares during the period. Norges Bank purchased a new position in shares of Corcept Therapeutics in the 4th quarter valued at approximately $24,213,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Corcept Therapeutics in the 2nd quarter valued at approximately $49,185,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In related news, Director James N. Wilson sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $110.69, for a total value of $1,106,900.00. Following the completion of the transaction, the director owned 1,064,543 shares of the company’s stock, valued at approximately $117,834,264.67. The trade was a 0.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Sean Maduck sold 25,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $114.43, for a total transaction of $2,860,750.00. Following the completion of the transaction, the insider owned 9,755 shares in the company, valued at approximately $1,116,264.65. This trade represents a 71.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 446,415 shares of company stock valued at $50,674,595. 20.70% of the stock is owned by company insiders.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

Positive Sentiment: The European Medicines Agency’s CHMP recommended marketing authorization for Lifyorli (relacorilant) combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The recommendation moves Corcept closer to a potential European launch, expanding the commercial opportunity for its oncology pipeline, although final approval by the European Commission is still required. Corcept receives CHMP recommendation
Positive Sentiment: HC Wainwright reaffirmed its Buy rating and maintained a $165 price target, implying substantial upside from recent trading levels. The bullish view reflects optimism about Lifyorli’s regulatory progress and Corcept’s growth potential.
Positive Sentiment: Zacks Research raised several longer-term EPS forecasts, including its FY2027 estimate to $2.05 from $1.91 and FY2028 estimate to $4.31 from $4.07. These revisions suggest analysts see improving earnings potential as new products contribute to revenue.
Neutral Sentiment: Reports highlighted Corcept among companies benefiting from favorable European drug recommendations, reinforcing the visibility of the Lifyorli regulatory milestone. EU drug recommendations
Negative Sentiment: James Wilson, a Corcept director, sold 10,000 shares for approximately $1.11 million, while another insider previously sold 10,000 shares. Wilson still retains more than 1.06 million shares, limiting the significance of the transaction, but insider selling can weigh on investor sentiment.
Negative Sentiment: Zacks’ FY2026 EPS estimate of $1.39 is below the broader full-year consensus of $2.02, indicating some concern about near-term earnings expectations despite stronger later-year forecasts.

Analyst Ratings Changes

Several equities analysts have issued reports on CORT shares. Canaccord Genuity Group boosted their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Piper Sandler restated an “overweight” rating and set a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research report on Thursday, July 30th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a report on Monday, July 27th. Weiss Ratings downgraded shares of Corcept Therapeutics from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, September 8th. Finally, UBS Group set a $135.00 price target on Corcept Therapeutics in a research note on Thursday, May 28th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $138.17.

View Our Latest Analysis on Corcept Therapeutics

Corcept Therapeutics Trading Down 4.0%

Shares of NASDAQ CORT opened at $110.29 on Friday. The company’s 50-day moving average price is $108.56 and its 200 day moving average price is $75.21. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $126.38. The stock has a market cap of $11.92 billion, a price-to-earnings ratio of 262.60 and a beta of 0.45.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.34. The company had revenue of $256.15 million for the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The company’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.29 earnings per share. As a group, research analysts expect that Corcept Therapeutics Incorporated will post 1.86 earnings per share for the current year.

Corcept Therapeutics Company Profile

(Free Report)

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.